Plasma circulating microRNAs in patients with stable coronary artery disease - Impact of different cardiovascular risk profiles and glomerular filtration rates.
SYNTAX score
coronary artery disease
microRNA-126
microRNA-145
microRNA-155
Journal
Journal of clinical and translational research
ISSN: 2424-810X
Titre abrégé: J Clin Transl Res
Pays: Singapore
ID NLM: 101667205
Informations de publication
Date de publication:
22 Apr 2021
22 Apr 2021
Historique:
received:
02
02
2021
revised:
27
03
2021
accepted:
27
03
2021
entrez:
9
6
2021
pubmed:
10
6
2021
medline:
10
6
2021
Statut:
epublish
Résumé
Plasma circulating microRNA (miRNA)-126, -145, and -155 are associated with vascular remodeling, atherosclerotic lesion formation, and plaque vulnerability. In this study, we evaluated the levels of plasma circulating miRNAs in patients with stable coronary artery disease (CAD), different cardiovascular risk profiles, and different glomerular filtration rates (GFR). Forty patients with stable CAD admitted for elective percutaneous coronary intervention (PCI) were enrolled in a prospective study. Before PCI, fasting blood samples were obtained to evaluate clinical parameters and miRNA-126 and miRNA-155 expression. The GFR was calculated by the MDRD and CKD-EPI formulas, and the severity of CAD was calculated according to the SYNTAX score. All these parameters were correlated with miRNAs. The association between miRNA levels and clinical characteristics was evaluated. The expression of miRNA-126 positively correlated with a higher SYNTAX score (r = 0.337; p=0.034); however, no significant correlations between miR-126, GFR, and clinical characteristics were observed. Higher plasma levels of miRNA-155 correlated with increased levels of triglycerides (r = 0.317; P = 0.049), C-peptide (r = 0.452; P = 0.011), and the HOMA index (r = 0.447; P = 0.012) and a higher body mass index (BMI) (r = 0.385; P = 0.015). GFR and miRNA-155 (MDRD - Rho=0.353; P = 0.027. CKD-EPI - Rho=0.357; P = 0.026) were found to have a moderate correlation, although miRNA-155 had no correlation with the SYNTAX score. Plasma circulating miRNA-126 levels were increased in patients with severe atherosclerosis as determined by the SYNTAX score. Elevated miRNA-155 expression was observed in patients with Stage 1 GFR but was lower in patients with Stages 2 and 3 GFR. Plasma circulating miRNA-155 had positive correlations with higher levels of BMI, HOMA index, C-peptide, and triglycerides. Although further investigations are needed to confirm the role of miRNA-155 and miRNA-126, they may serve as potential biomarkers detecting severity of CAD, lowering of kidney function and metabolic syndrome.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
Plasma circulating microRNA (miRNA)-126, -145, and -155 are associated with vascular remodeling, atherosclerotic lesion formation, and plaque vulnerability. In this study, we evaluated the levels of plasma circulating miRNAs in patients with stable coronary artery disease (CAD), different cardiovascular risk profiles, and different glomerular filtration rates (GFR).
METHODS AND RESULTS
RESULTS
Forty patients with stable CAD admitted for elective percutaneous coronary intervention (PCI) were enrolled in a prospective study. Before PCI, fasting blood samples were obtained to evaluate clinical parameters and miRNA-126 and miRNA-155 expression. The GFR was calculated by the MDRD and CKD-EPI formulas, and the severity of CAD was calculated according to the SYNTAX score. All these parameters were correlated with miRNAs. The association between miRNA levels and clinical characteristics was evaluated. The expression of miRNA-126 positively correlated with a higher SYNTAX score (r = 0.337; p=0.034); however, no significant correlations between miR-126, GFR, and clinical characteristics were observed. Higher plasma levels of miRNA-155 correlated with increased levels of triglycerides (r = 0.317; P = 0.049), C-peptide (r = 0.452; P = 0.011), and the HOMA index (r = 0.447; P = 0.012) and a higher body mass index (BMI) (r = 0.385; P = 0.015). GFR and miRNA-155 (MDRD - Rho=0.353; P = 0.027. CKD-EPI - Rho=0.357; P = 0.026) were found to have a moderate correlation, although miRNA-155 had no correlation with the SYNTAX score.
CONCLUSION
CONCLUSIONS
Plasma circulating miRNA-126 levels were increased in patients with severe atherosclerosis as determined by the SYNTAX score. Elevated miRNA-155 expression was observed in patients with Stage 1 GFR but was lower in patients with Stages 2 and 3 GFR. Plasma circulating miRNA-155 had positive correlations with higher levels of BMI, HOMA index, C-peptide, and triglycerides.
RELEVANCE FOR PATIENTS
UNASSIGNED
Although further investigations are needed to confirm the role of miRNA-155 and miRNA-126, they may serve as potential biomarkers detecting severity of CAD, lowering of kidney function and metabolic syndrome.
Identifiants
pubmed: 34104831
pii: jctres.07.202102.014
pmc: PMC8177841
Types de publication
Journal Article
Langues
eng
Pagination
270-276Informations de copyright
Copyright: © Whioce Publishing Pte. Ltd.
Déclaration de conflit d'intérêts
None declared.
Références
Thromb J. 2012 Aug 28;10(1):16
pubmed: 22925274
Cell Physiol Biochem. 2016;39(3):837-46
pubmed: 27497911
J Clin Endocrinol Metab. 2016 Apr;101(4):1615-26
pubmed: 26829440
Circ Res. 2010 Sep 3;107(5):677-84
pubmed: 20595655
Circ Res. 2014 Jun 6;114(12):1852-66
pubmed: 24902970
Atherosclerosis. 2016 Nov;254:271-281
pubmed: 27693002
PLoS One. 2013 May 22;8(5):e64558
pubmed: 23717629
Sci Rep. 2019 Mar 14;9(1):4477
pubmed: 30872798
Cell. 1993 Dec 3;75(5):843-54
pubmed: 8252621
Rev Esp Cardiol. 2008 Mar;61(3):299-310
pubmed: 18361904
Eur Heart J. 2011 Jul;32(14):1769-818
pubmed: 21712404
Circulation. 2012 Sep 11;126(11 Suppl 1):S81-90
pubmed: 22965997
J Clin Transl Res. 2020 Jan 13;5(2):60-67
pubmed: 32377580
Adv Exp Med Biol. 2017;960:197-220
pubmed: 28585200
Circ Res. 2016 Feb 19;118(4):703-20
pubmed: 26892968
PLoS One. 2018 Mar 21;13(3):e0192895
pubmed: 29561894
Arterioscler Thromb Vasc Biol. 2013 Mar;33(3):449-54
pubmed: 23324496
Int J Mol Sci. 2019 May 13;20(9):
pubmed: 31085992
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1608-1617
pubmed: 28775076
Sci Signal. 2009 Dec 08;2(100):ra81
pubmed: 19996457
Trends Mol Med. 2015 May;21(5):307-18
pubmed: 25771097
Biochim Biophys Acta. 2010 Nov;1803(11):1231-43
pubmed: 20619301
Hypertension. 2003 Oct;42(4):507-14
pubmed: 12963678
Front Immunol. 2019 Apr 17;10:799
pubmed: 31057539
PLoS One. 2014 Feb 19;9(2):e89237
pubmed: 24586621
Diabetes Metab Syndr. 2017 Nov;11 Suppl 1:S307-S309
pubmed: 28365222
Nephrol Dial Transplant. 2011 Nov;26(11):3794-802
pubmed: 21891774
Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):485-91
pubmed: 25717174
Am J Physiol Renal Physiol. 2020 Feb 1;318(2):F315-F321
pubmed: 31813253
Front Pharmacol. 2019 May 14;10:463
pubmed: 31139076
Am J Med. 2015 Sep;128(9):1015-22.e2
pubmed: 25863153